• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Early changes in albuminuria with Canagliflozin predicts kidney and cardiovascular outcomes

byBrian DoughertyandAlex Chan
October 6, 2020
in Cardiology, Endocrinology, Nephrology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

RELATED REPORTS

Catheter ablation reduces rates of persistent atrial fibrillation and atrial tachyarrhythmia

Empagliflozin use is associated with slower progression of chronic kidney disease

Metformin use in Type 2 Diabetes associated with decreased risk of joint replacement

1. Among patients with type 2 diabetes mellitus and chronic kidney disease being treated with canagliflozin, earlier reductions in albuminuria were associated with a decreased risk of adverse renal and cardiovascular outcomes.

Evidence Level Rating: 2 (Good)

In the past, post hoc analyses from clinical trials of RAAS inhibitors have shown that the magnitude of reduction of albuminuria – a strong, independent risk marker of cardiovascular and kidney disease – is associated with the degree of risk reduction. The 2019 Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial demonstrated that the SGLT2 inhibitor canagliflozin, originally developed a glucose-lowering agent, results in a sustained reduction in albuminuria and confers a reduced risk of kidney failure and poor cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD). This post hoc analysis of the CREDENCE trial sought to answer whether early reductions in albuminuria are associated with the magnitude of risk reduction, similar to what has been observed in RAAS-modulated drugs. Briefly, CREDENCE was a double-blind, placebo-controlled randomized trial involving 4,401 patients randomized to receive 100 mg of canagliflozin daily, or matching placebo. The cohort in this analysis included 3,836 participants from CREDENCE. The primary kidney outcome was a composite of ESRD (defined as dialysis for at least 30 days, kidney transplantation, or an eGFR of < 15 mL/min/1.73 m2 sustained for at least 30 days), doubling of the serum creatinine level from baseline sustained for at least 30 days, or kidney death. The primary cardiovascular outcomes were major adverse cardiovascular events (MACE), defined as a composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke, as well as a composite of hospitalization for heart failure or cardiovascular death. Overall, it was found that an early reduction in urine albumin-to-creatinine ratio (UACR) was associated favorably with kidney and cardiovascular outcomes. Indeed, each 30% decrease in UACR over the first 26 weeks of treatment was associated with significant hazard reductions for the kidney (HR 0.71, 95% CI 0.67 to 0.76, p < 0.001), MACE (HR 0.92, 95% CI 0.88 to 0.96, p < 0.001), and hospitalizations for heart failure or cardiovascular death (HR 0.86, 95% CI 0.81 to 0.90, p < 0.001) outcomes. Furthermore, the association between early reduction in UACR and the kidney outcome was stronger among patient with a lower eGFR and higher UACR; in contrast, the associations were consistent for the cardiovascular outcomes. In all, this post hoc analysis suggests that an early reduction in UACR during treatment with canagliflozin is associated with a reduced risk of adverse kidney and cardiovascular outcomes among patients with T2DM and CKD, highlighting the importance of tracking albuminuria to both guide treatment and assess prognosis.

Click to read the study in JASN

Image: PD

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: cardiologydiabetesnephrology
Previous Post

#VisualAbstract: Appropriate knowledge of HPV vaccine important for uptake among college-age young adults

Next Post

#VisualAbstract: COVID-19 associated with cardiac manifestations in pediatric patients

RelatedReports

β-blockers linked to improved survival in preserved ejection fraction heart failure
Cardiology

Catheter ablation reduces rates of persistent atrial fibrillation and atrial tachyarrhythmia

January 27, 2023
Fish oil and aspirin did not reduce arteriovenous fistula failure: The FAVOURED trail
Cardiology

Empagliflozin use is associated with slower progression of chronic kidney disease

January 26, 2023
Type 2 diabetes associated with reduction in disability-free life years
Chronic Disease

Metformin use in Type 2 Diabetes associated with decreased risk of joint replacement

January 16, 2023
Remote patient monitoring did not reduce heart failure readmissions: The BEAT-HF trial
Cardiology

Clinical decision-making strategy improves acute heart failure outcomes

January 12, 2023
Next Post
#VisualAbstract: Sarcopenia associated with reduced muscle mass and strength following liver resection for malignant neoplasms

#VisualAbstract: COVID-19 associated with cardiac manifestations in pediatric patients

Peanut allergy effectively treated with oral immunotherapy: the PALISADE trial

Halloween and Easter associated with increased rates of anaphylaxis in Canadian pediatric patients

Active malignancy during COVID-19 infection not associated with increased risk of ICU admission, intubation, or death

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • BNT162b2 booster is safe and reduces COVID-19 transmission in older adults
  • Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosozumab reduce postmenopausal fracture risk
  • Epstein-Barr viral load monitoring reduces risk of post-liver transplant lymphoproliferative disease
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options